Jacobs Renews Alliance Contract With GSK In Singapore
Engineering Group Inc. (NYSE:JEC) announced today it has renewed its
contract with Glaxo Wellcome Manufacturing Pte Ltd (GSK) as alliance
contractor at GSK’s two manufacturing facilities in Singapore.
Jacobs Engineering Group Inc. (NYSE:JEC) announced today it has renewed its contract with Glaxo Wellcome Manufacturing Pte Ltd (GSK) as alliance contractor at GSK’s two manufacturing facilities in Singapore. The renewal is a continuation of the initial alliance program with GSK in Singapore. Officials did not disclose the contract value, however noted the contract is for two years, with the option to be renewed for an additional two years. Under the terms of the alliance contract, Jacobs is providing engineering, procurement, project management, construction management and validation services. Jacobs Group Vice President Tom Quinn stated, “We are very pleased that GSK has renewed its alliance partnership with Jacobs. This is the continuation of a ten year working relationship between Jacobs and GSK in Singapore. We appreciate their confidence in our performance, and are committed to continuing to deliver superior value to GSK.” GlaxoSmithKline – with offices in more than 115 countries – is one of the world’s leading research-based pharmaceutical and healthcare companies. Jacobs is one of the world's largest and most diverse providers of technical, professional, and construction services. Statements made in this release that are not based on historical fact are forward-looking statements. We base these forward-looking statements on management’s current estimates and expectations as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2012 Form 10-K, and in particular the discussions contained under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We do not undertake to update any forward-looking statements made herein.